BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 542 | Download: 659
Publication Name World Journal of Gastroenterology
Manuscript ID 5399
Country/Territory China
Received
2013-09-05 08:42
Peer-Review Started
2013-09-05 11:27
To Make the First Decision
2013-09-27 16:54
Return for Revision
2013-09-29 10:30
Revised
2013-10-08 22:16
Second Decision
2013-11-04 17:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-05 10:03
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-11-13 18:16
Typeset the Manuscript
2013-12-16 11:54
Publish the Manuscript Online
2014-01-20 16:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Qing He, Wu-Sheng Lu, Yang Liu, Yong-Song Guan and An-Ren Kuang
Funding Agency and Grant Number
Corresponding author Dr. An-Ren Kuang, Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. kuanganren@263.net
Keywords Hepatocellular carcinoma; 131I-metuximab; Transcatheter arterial chemoembolization; Radioimmunotherapy
Core Tip 131I-metuximab has high affinity with a target antigen highly expressed on hepatocellular carcinoma (HCC) cells and a limited area of action. The combination of metuximab and transcatheter arterial chemoembolization had a synergistic effect in the treatment of HCC. It may represent a promising treatment modality for patients with advanced HCC, especially for those patients with multiple nodules who have a heavy tumor burden.
Publish Date 2014-01-20 16:41
Citation He Q, Lu WS, Liu Y, Guan YS, Kuang AR. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 9104-9110
Url http://www.wjgnet.com/1007-9327/full/v19/i47/9104.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i47.9104
Full Article (PDF) WJG-19-9104.pdf
Manuscript File 5399-Review.doc
Answering Reviewers 5399-Answering reviewers.pdf
Copyright License Agreement 5399-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5399-Language certificate.pdf
Peer-review Report 5399-Peer review(s).pdf
Scientific Editor Work List 5399-Scientific editor work list.doc